Charlotte Cave, a 3-year old girl is battling B-Cell Acute Lymphoblastic Leukemia, along with medical trauma and anxiety.

EBBH-2024 is under clinical development by Essen Biotech and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL).

Hematologist-oncologists are doctors who specialize in treating blood cancers such as acute lymphoblastic leukemia (ALL). ALL is a rare, rapidly progressing cancer of the blood and bone marrow.

AT-19 is under clinical development by Shanghai YaKe Biotechnology and currently in Phase II for Chronic Lymphocytic Leukemia (CLL).

Josep Maria Ribera, MD, PhD, discusses the current standard treatment protocols for Philadelphia chromosome-positive acute lymphoblastic leukemia and the rationale behind them.

Survival rates for childhood leukemia are improving thanks to new treatments. Acute lymphoblastic leukemia has the highest survival among all pediatric cancers, 80-85 percent. Seattle Children’s ...

Emilio Nares would have turned 30 years old Monday. For his parents, Diane and Richard, his birthdays are sacred. They don’t ...

A brief neurocognitive battery is feasible for use in 3-year-olds during acute lymphoblastic leukemia treatment, according to ...

HealthDay News — For patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), obecabtagene autoleucel (obe-cel), an autologous 41BB-ζ anti-CD19 chimeric antigen receptor (CAR) T ...

A brief neurocognitive battery is feasible for use in 3-year-olds during acute lymphoblastic leukemia treatment, according to a study published online Dec. 9 in Pediatric Blood & Cancer.

Blinatumomab in addition to standard chemotherapy improved pediatric patients with NCI standard-risk B-cell acute lymphoblastic leukemia survival outcomes.